MAPLE SYRUP URINE DISEASE - INTERRELATIONS BETWEEN BRANCHED-CHAIN AMINO-ACIDS, OXO-ACIDS AND HYDROXYACIDS - IMPLICATIONS FOR TREATMENT - ASSOCIATIONS WITH CNS DYSMYELINATION

被引:72
作者
TREACY, E
CLOW, CL
READE, TR
CHITAYAT, D
MAMER, OA
SCRIVER, CR
机构
[1] MCGILL UNIV, MONTREAL CHILDRENS HOSP,RES INST, DEBELLE LAB BIOCHEM GENET,2300 TUPPER ST, MONTREAL H3H 1P3, QUEBEC, CANADA
[2] MCGILL UNIV, BIOMED MASS SPECTROMETRY UNIT, MONTREAL H3H 1P3, QUEBEC, CANADA
关键词
D O I
10.1007/BF01800354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Four patients with classical maple syrup urine disease were treated for up to 5885 days per patient with a relaxed protocol allowing branched-chain amino acid levels in plasma to rise about 5 times the normal mean value. The patients have had satisfactory development and lifestyle. They spent 318 days in hospital during 19 937 aggregate treatment days. Plasma levels of leucine and the corresponding 2-oxo acid were shown to be elevated disproportionately relative to the other branched-chain metabolites. Levels of isoleucine and valine were lower than those of leucine apparently because of runout into alternative metabolite pools, namely the R metabolites for isoleucine and the hydroxyacid for valine. The chronic accumulation of branched-chain 2-oxo acid(s) in our patients was associated with chronic dysmyelinating changes in CNS visible by imaging. Another patient with a thiamine-responsive variant of maple syrup urine disease had five acute crises incurring 29 days in hospital in a total of 6910 treatment days. However, she did not have chronic metabolic dyshomeostasis (her average plasma amino acid values were normal) and she had no evidence of dysmyelination. A relaxed treatment protocol for patients with maple syrup urine disease may benefit them in quality of life, but it apparently exacts a cost in metabolic control and CNS pathology.
引用
收藏
页码:121 / 135
页数:15
相关论文
共 36 条
[31]   ACUTE METABOLIC ENCEPHALOPATHY - A REVIEW OF CAUSES, MECHANISMS AND TREATMENT [J].
SURTEES, R ;
LEONARD, JV .
JOURNAL OF INHERITED METABOLIC DISEASE, 1989, 12 :42-54
[32]   PROTEIN AND LEUCINE METABOLISM IN MAPLE SYRUP URINE DISEASE [J].
THOMPSON, GN ;
BRESSON, JL ;
PACY, PJ ;
BONNEFONT, JP ;
WALTER, JH ;
LEONARD, JV ;
SAUDUBRAY, JM ;
HALLIDAY, D .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 258 (04) :E654-E660
[33]   MYELIN PROTEINS - DEGRADATION IN RAT-BRAIN INITIATED BY METABOLITES CAUSATIVE OF MAPLE SYRUP URINE DISEASE [J].
TRIBBLE, D ;
SHAPIRA, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1983, 114 (02) :440-446
[34]   CT AND MRI IN MAPLE SYRUP URINE DISEASE [J].
UZIEL, G ;
SAVOIARDO, M ;
NARDOCCI, N .
NEUROLOGY, 1988, 38 (03) :486-488
[35]   INTERRELATION BETWEEN THE METABOLISM OF L-ISOLEUCINE AND L-ALLO-ISOLEUCINE IN PATIENTS WITH MAPLE SYRUP URINE DISEASE [J].
WENDEL, U ;
LANGENBECK, U ;
SEAKINS, JWT .
PEDIATRIC RESEARCH, 1989, 25 (01) :11-14
[36]   THE 2-OXO ACID DEHYDROGENASE COMPLEXES - RECENT ADVANCES [J].
YEAMAN, SJ .
BIOCHEMICAL JOURNAL, 1989, 257 (03) :625-632